Some possible good news on prostate cancer- The Guardian

This was in today’s Guardian.

Prostate cancer trial stuns researchers: ‘It’s a once in a career feeling’ – Study with ‘powerful results’ finds that combining two existing therapies could extend the life of men with advanced, high-risk prostate cancer by 37%. Combining two existing prostate cancer therapies could extend the life of men with advanced, high-risk prostate cancer by 37%, according to a study presented at the world’s largest cancer conference. The new findings could change how doctors first approach treatment of prostate cancer.

https://www.theguardian.com/society/2017/jun/03/prostate-cancer-therapy-study-abiraterone?utm_source=esp&utm_medium=Email&utm_campaign=GU+Today+USA+-+Collections+2017&utm_term=229027&subid=9822000&CMP=GT_US_collection

Payer snubs PTC’s Emflaza, signaling pricing trouble ahead of launch – FiercePharma

Washington State continues to battle for lower cost prescriptions. This is your government in action. It’s a good thing.

As Washington State’s HCA noted, PTC Therapeutics has not announced its new price. But the group published a report (PDF) stating that prednisone—at a cost of 5 cents per tablet and $55 per year—will be its preferred corticosteroid for DMD patients. It’s the “lower cost, equally effective” option, according to HCA.

Read the whole story here:

http://www.fiercepharma.com/pharma/policy-report-washington-s-largest-healthcare-purchaser-snubs-ptc-s-emflaza